newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

  • IGC Pharma filed its Form 10-KT for the nine months ended December 31, 2025, after shifting its fiscal year-end from March 31 to December 31.
  • The Phase 2 CALMA trial for lead candidate IGC-AD1 has surpassed 70% enrollment, targeting agitation in Alzheimer's dementia.
  • Net loss for common stockholders improved by $1.8 million to $4.1 million, down from $5.9 million in the prior period.
  • Research amp; Development expenses increased 48% to $4.0 million due to trial expansion amp; advancement of the IGC-M3 preclinical program.
  • Revenue totaled $869 thousand, reflecting a transition from white-label manufacturing to core pharmaceutical amp; AI assets.
  • The Company divested a non-core manufacturing facility for $2.7 million, generating a $1.1 million non-cash profit amp; reducing annual operating expenses by approximately $600 thousand.
  • The AI team received an award from the National Institute on Aging amp; was named an ADDI semi-finalist.
  • Two U.S. patents were issued: No. 12,491,200 for a microdose cannabinoid treatment for stuttering/Tourette's amp; No. 12,465,589 for the IGC-AD1 proprietary formulation.
  • Positive in-vitro findings were reported for pipeline candidates IGC-1C (tau pathways) amp; IGC-M3 (amyloid aggregation/neuroinflammation).
  • FYE 2026 catalysts include finalizing CALMA enrollment, expanding IGC-AD1 indications to sleep disturbances, seeking strategic partnerships, amp; monetizing MINT-AD amp; AHA AI platforms.